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Introduction
GABA and glycine are major inhibitory neurotransmitters.
GABAA and glycine receptors (GlyR) form pentameric
chloride channels and belong to the Cys-loop receptor
superfamily with 5-HT3 serotonin and nicotinic receptors.
Homology modelling has revealed distinctive binding
interactions of antagonists and agonists in the interface of
5-HT3A receptors leading to ligand translocation, closure
of the binding cavity and ionophore activation. Allosteric
modulation of ionotropic receptors enables the pharma-
cological fine-tuning of neurotransmission.
Methods
Radioligand binding of [3H]EBOB and [3H]strychnine to
native GABAA and recombinant GlyRs, respectively, and
whole-cell patch clamp electrophysiology in cultured rat
cerebellar granule cells.
Results
A 17β-alkenyl derivative of the neurosteroid allopregna-
nolone antagonized the potentiating effects of allopregna-
nolone selectively on a cerebellar (α6βδ) population of
GABAA receptors with nanomolar potency. Nortropine
esters exerted bidirectional allosteric modulation of
GlyRs: nor-O-zatosetron had the highest affinity reported
for GlyRs. The anaesthetic propofol restored the potency
of glycine impaired by a point mutation R271L of GlyR α1
subunits leading to hyperekplexia, an inherited neurolog-
ical disorder.
Conclusion
Some of these allosteric modulators have nanomolar
potencies and serve as promising leads for subunit-selec-
tive modulation of ionotropic receptors.
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